|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggested that PAX3 may be a biomarker and essential prognostic factor for melanoma, and provided an important theoretical basis for the development of melanoma treatments.
|
31186709 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The transcription factors PAX3 and FOXD3 have essential roles in melanoblasts and melanoma.
|
26252164 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore examined the therapy phase before acquired resistance had developed and discovered the melanoma survival oncogene MITF as a driver of an early non-mutational and reversible drug-tolerance state, which is induced by PAX3-mediated upregulation of MITF.
|
26977879 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we discover a molecular pathway wherein PAX3 and FOXD3 promote CXCR4 gene expression in melanoma.
|
26205821 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our findings suggest a tumor suppressor role for APC/C(Cdh1) in melanocytes and that targeting PAX3 may be a strategy for treating melanoma.
|
26329581 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further studies are needed to examine the role of PAX3 in melanoma susceptibility.
|
23751107 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To understand how PAX3 affects melanocyte and melanoma proliferation, we identified potential PAX3 downstream targets through gene expression profiling.
|
23020925 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
|
22988297 |
2012 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Deregulated expression of PAX3 has been observed in tumors like rhabdomyosarcoma and melanomas.
|
22231626 |
2012 |
|
melanoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These data support a model wherein GSK-3 regulates proliferation and morphology of melanoma through phosphorylation and increased levels of PAX3.
|
22679108 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that by controlling cell proliferation, survival and migration as well as maintaining a less differentiated "stem" cell like phenotype, PAX3 may contribute to melanoma development and progression.
|
21802410 |
2011 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).
|
20421967 |
2010 |
|
melanoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
(4) Amplification of chromosome 3p and hypo-methylation of PAX3 together elevate MITF expression in melanoma, which up-regulates the downstream targets of MITF.
|
20925909 |
2010 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previously published primer designs were tested for PAX3 and GalNAc-T and revealed that alternative PAX3 transcripts are differentially expressed in melanoma and benign lymph nodes.
|
18982394 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In light of the plethora of information gleaned from development we then consider its roles in melanoma and provide here a comprehensive consideration of the significance of PAX3 expression in melanoma.
|
19401874 |
2009 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, PAX3 is involved in rhabdomyosarcoma and tumours of neural crest origin, including melanoma and neuroblastoma.
|
18627422 |
2008 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Our data suggest that PAX3-expressing melanomas may be less environmentally dependent and more genetically linked.
|
18327212 |
2008 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further analysis of our melanoma set revealed that PAX3 expression is strongly correlated with younger patients with low or no evidence of sun damage.
|
18327212 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Functional analysis of alternative isoforms of the transcription factor PAX3 in melanocytes in vitro.
|
16951170 |
2006 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using PAX3-specific antisense oligodeoxynucleotides (PAX3-AS) to treat melanoma cell lines in vitro, we showed dose-dependent reduction of proliferation of melanoma cells, and induction of apoptosis compared with control treatments.
|
15956257 |
2005 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Pax3 transcripts in melanoblast development.
|
16316407 |
2005 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One was identified as PAX3, and its isoform, PAX3d, was found to be dominantly expressed in melanoma and melanocytes.
|
15614040 |
2005 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since no one has investigated the expression of the isoforms of PAX 3 in the neuroectodermal tumors melanoma and small cell lung cancer (SCLC), we have carried out a comprehensive screening for the expression of the isoforms PAX 3a-e using RT-PCR in human melanoma cell lines, primary human ocular and secondary cutaneous melanomas.
|
14639621 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Annexin V staining confirmed that primary melanoma cells underwent apoptosis after treatment These experiments suggest that in situ hybridization of PAX3 on paraffin-embedded tissue may represent a novel means to identify melanoma cell lesions, which appear to become dependent on expression of this deregulated transcription factor.
|
11221862 |
2001 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found here that the Pax 3 mRNA was expressed in all melanoma cell lines, even in those that had repressed the MITF-M and were amelanotic.
|
10644012 |
1999 |